logo-loader
viewTiziana Life Sciences PLC

Tiziana plans to 'unlock value of StemPrintER asset by listing Accustem Sciences before year end'

Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone talks to Proactive London about his plan to 'unlock the value of their Stemprinter asset for shareholders by listing Accustem Sciences Ltd before year end'.

Cerrone goes on to explain how the timeline will work and how the distribution in the specie proposed capital reduction will happen.

Quick facts: Tiziana Life Sciences PLC

Price: 142 GBX

AIM:TILS
Market: AIM
Market Cap: £271.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

4 days, 14 hours ago

2 min read